<DOC>
	<DOCNO>NCT00005046</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness paclitaxel treat patient recurrent persistent ovarian primary peritoneal cancer .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Recurrent Persistent Ovarian Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety tolerability intraperitoneal administration paclitaxel ( Paclimer microspheres ) patient recurrent persistent ovarian primary peritoneal carcinoma . II . Determine confirm maximum tolerate dose regimen patient population . III . Determine plasma paclitaxel concentration select time intraperitoneal administration Paclimer microspheres patient . OUTLINE : This dose escalation study . Patients receive intraperitoneal paclitaxel ( Paclimer microspheres ) every 8 week 2 course . Cohorts 1-3 patient receive escalate dos intraperitoneal paclitaxel ( Paclimer microspheres ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose limit toxicity . Once probable MTD determine , additional cohort 8 patient accrue confirm MTD . The MTD confirm dose level least 6 8 patient demonstrate acceptable safety tolerability . PROJECTED ACCRUAL : A maximum 24 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Recurrent persistent ovarian and/or primary peritoneal carcinoma Adequate potential intraperitoneal fluid distribution gross fluid loculations adhesion would significantly affect intraperitoneal drug distribution PATIENT CHARACTERISTICS : Age : 21 Performance status : GOG 02 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 WBC least 3,000/mm3 Platelet count least 100,000/mm3 Granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal Renal : Creatinine le 2.0 mg/dL Other : No sufficiently severe medical problem unrelated malignancy would preclude study compliance cause exposure undue risk No prior unmanageable reaction paclitaxel PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior myelosuppressive chemotherapy ( 6 week nitrosourea mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy major bone marrow contain area Surgery : Not specify Other : At least 1 month since prior investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>